While Intellia Therapeutics Inc has underperformed by -3.69%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, NTLA fell by -46.75%, with highs and lows ranging from $47.48 to $19.37, whereas the simple moving average fell by -23.00% in the last 200 days.
On February 23, 2024, Goldman Downgraded Intellia Therapeutics Inc (NASDAQ: NTLA) to Neutral. A report published by Wolfe Research on February 15, 2024, Initiated its previous ‘Peer Perform’ rating for NTLA. Canaccord Genuity also rated NTLA shares as ‘Buy’, setting a target price of $66 on the company’s shares in an initiating report dated April 13, 2023. Bernstein Initiated an Outperform rating on March 21, 2023, and assigned a price target of $54. BMO Capital Markets March 14, 2023d its ‘Market Perform’ rating to ‘Outperform’ for NTLA, as published in its report on March 14, 2023. Cantor Fitzgerald’s report from February 01, 2023 suggests a price prediction of $67 for NTLA shares, giving the stock a ‘Overweight’ rating. Citigroup also rated the stock as ‘Neutral’.
Analysis of Intellia Therapeutics Inc (NTLA)
Further, the quarter-over-quarter decrease in sales is -114.12%, showing a negative trend in the upcoming months.
Intellia Therapeutics Inc’s future performance can be determined with the help of several well-rounded types of analysis and research techniques, with equity being one of the most influential. The goal here is to ensure that your current return on equity of -42.10% is sufficient for you to turn a profit off your investment. Taking into account the quick ratio of the company, currently set at 8.67, you can see that the company can cover any debts it may have, which can easily be seen in the annual report of the company.
The average volume for any stock is also a very valuable indicator of volatility, and NTLA has an average volume of 1.48M. On a monthly basis, the volatility of the stock is set at 5.05%, whereas on a weekly basis, it is put at 4.38%, with a gain of 2.22% over the past seven days. Furthermore, long-term investors anticipate a median target price of $69.57, showing growth from the present price of $23.00, which can serve as yet another indication of whether NTLA is worth investing in or should be passed over.
How Do You Analyze Intellia Therapeutics Inc Shares?
In addition to analyzing the fundamentals, it is also important to look at how many company employees own stock. This is because the values should be in line with investors’ expectations. As such, the current holdings of company stock inside the company are set at 2.33%. This can enable you to see the extent to which executives own the company’s stock. As opposed to executive stock, institutional ownership accounts for 84.94% of the company’s shares, contributing to an indication of company value, since large shareholders may signify strength within the organization.
NTLA shares are owned by institutional investors to the tune of 84.94% at present.
